Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -53% Improvement Relative Risk Cravedi et al. HCQ for COVID-19 LATE TREATMENT Favors HCQ Favors control
COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium
Cravedi et al., American Journal of Transplantation, doi:10.1111/ajt.16185
Cravedi et al., COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium, American Journal of Transplantation, doi:10.1111/ajt.16185
Jul 2020   Source   PDF  
  All Studies   Meta
Analysis of 144 hospitalized kidney transplant patients showing HCQ mortality HR 1.53, p = 0.17. Subject to confounding by indication. This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely.
risk of death, 53.0% higher, RR 1.53, p = 0.17, treatment 36 of 101 (35.6%), control 10 of 43 (23.3%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cravedi et al., 10 Jul 2020, retrospective, USA, peer-reviewed, mean age 60.0, 25 authors, average treatment delay 6.0 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Received: 18 May 2020 | | Revised: 24 June 2020 Accepted: 25 June 2020 DOI: 10.1111/ajt.16185 B R I E F C O M M U N I C AT I O N COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium Paolo Cravedi1 | Suraj S. Mothi2 | Yorg Azzi3 | Meredith Haverly1 | Samira S. Farouk4 | 5 5 1 4 María J. Pérez-Sáez | Maria D. Redondo-Pachón | Barbara Murphy | Sander Florman | 2 Laura G. Cyrino | Monica Grafals6 | Sandheep Venkataraman6 | Xingxing S. Cheng7 | 7 8 9 10 Aileen X. Wang | Gianluigi Zaza | Andrea Ranghino | Lucrezia Furian | 11 Joaquin Manrique | Umberto Maggiore12 | Ilaria Gandolfini12 | Nikhil Agrawal13 | | Leonardo V. Riella14,15 Het Patel13 | Enver Akalin3 1 Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York 2 Schuster Transplantation Research Center, Brigham & Women’s Hospital, Harvard Medical School, Boston, Massachusetts 3 Division of Nephrology, Montefiore Medical Center Transplant Center, Albert Einstein College of Medicine, Bronx, New York 4 Recanati-Miller Transplantation Institute, Mount Sinai Hospital, New York, New York 5 Servicio de Nefrología, Hospital del Mar, Barcelona, Spain 6 Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado 7 Department of Medicine, Division of Nephrology, Stanford University School of Medicine, Stanford, Massachusetts 8 Renal Unit, Department of Medicine, University Hospital of Verona, Verona, Italy 9 SOD Nefrologia, Dialisi e Trapianto Rene, AOU Ospedali Riuniti, Ancona, Italy 10 Kidney and Pancreas Transplantation Unit, Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Padova, Italy 11 Nephrology Service, Complejo Hospitalario de Navarra, Pamplona, Spain 12 Dipartimento di Medicina e Chirurgia, Università di Parma, UO Nefrologia, Azienda Ospedaliera-Universitaria Parma, Parma, Italy 13 Division of Nephrology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 14 Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 15 Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts Correspondence Paolo Cravedi Email: Leonardo V. Riella Email: Kidney transplant recipients may be at a high risk of developing critical coronavirus disease 2019 (COVID-19) illness due to chronic immunosuppression and comorbidities. We identified hospitalized adult kidney transplant recipients at 12 transplant centers in the United States, Italy, and Spain who tested positive for COVID-19. Clinical presentation, laboratory values, immunosuppression, and treatment strategies were reviewed, and predictors of poor clinical outcomes were determined through multivariable analyses. Among 9845 kidney transplant recipients across centers, 144 were hospitalized due to COVID-19 during the 9-week study period. Of the 144 patients, 66% were male with a mean age of 60 (±12) years, and 40% were Hispanic and 25% Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CNI, calcineurin inhibitor; COVID-19, coronavirus disease 2019; IL, interleukin; MMF, mycophenolate mofetil; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2. Enver Akalin and Leonardo V. Riella are co-senior authors. Paolo Cravedi and Suraj Sarvode Mothi..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop